Goldman Sachs Group Inc Eagle Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 31,495 shares of EGRX stock, worth $18,267. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,495
Previous 79,093 60.18%
Holding current value
$18,267
Previous $442,000 73.76%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$3.71 - $6.07 $176,588 - $288,919
-47,598 Reduced 60.18%
31,495 $116,000
Q2 2024

Aug 13, 2024
SELL
$3.34 - $5.6 $329,704 - $552,798
-98,714 Reduced 55.52%
79,093 $442,000
Q1 2024

May 15, 2024
SELL
$4.26 - $6.51 $68,232 - $104,270
-16,017 Reduced 8.26%
177,807 $931,000
Q4 2023

Feb 13, 2024
BUY
$4.63 - $15.21 $150,803 - $495,404
32,571 Added 20.2%
193,824 $1.01 Million
Q3 2023

May 14, 2024
SELL
$15.21 - $22.88 $495,404 - $745,224
-32,571 Reduced 16.8%
161,253 $2.54 Million
Q3 2023

Nov 14, 2023
SELL
$15.21 - $22.88 $820,990 - $1.23 Million
-53,977 Reduced 25.08%
161,253 $2.54 Million
Q2 2023

May 14, 2024
BUY
$17.74 - $31.87 $810,434 - $1.46 Million
45,684 Added 26.94%
215,230 $4.18 Million
Q2 2023

Aug 14, 2023
BUY
$17.74 - $31.87 $810,434 - $1.46 Million
45,684 Added 26.94%
215,230 $4.18 Million
Q1 2023

May 14, 2024
BUY
$25.06 - $34.09 $692,959 - $942,656
27,652 Added 19.49%
169,546 $4.81 Million
Q1 2023

May 11, 2023
BUY
$25.06 - $34.09 $692,959 - $942,656
27,652 Added 19.49%
169,546 $4.81 Million
Q4 2022

May 14, 2024
BUY
$24.98 - $39.77 $804,780 - $1.28 Million
32,217 Added 29.37%
141,894 $4.15 Million
Q4 2022

Feb 13, 2023
BUY
$24.98 - $39.77 $804,780 - $1.28 Million
32,217 Added 29.37%
141,894 $4.15 Million
Q3 2022

May 14, 2024
SELL
$26.42 - $47.12 $1.48 Million - $2.63 Million
-55,905 Reduced 33.76%
109,677 $2.9 Million
Q3 2022

Nov 10, 2022
SELL
$26.42 - $47.12 $1.48 Million - $2.63 Million
-55,905 Reduced 33.76%
109,677 $2.9 Million
Q2 2022

May 14, 2024
SELL
$41.26 - $51.35 $1.17 Million - $1.45 Million
-28,242 Reduced 14.57%
165,582 $7.36 Million
Q2 2022

Aug 15, 2022
SELL
$41.26 - $51.35 $524,992 - $653,377
-12,724 Reduced 7.14%
165,582 $7.36 Million
Q1 2022

May 16, 2022
BUY
$44.58 - $52.6 $3.14 Million - $3.71 Million
70,438 Added 65.3%
178,306 $8.83 Million
Q4 2021

Feb 14, 2022
BUY
$45.82 - $56.9 $36,289 - $45,064
792 Added 0.74%
107,868 $5.49 Million
Q3 2021

Nov 10, 2021
BUY
$43.79 - $55.78 $4.69 Million - $5.97 Million
107,076 New
107,076 $5.97 Million

Others Institutions Holding EGRX

# of Institutions
70
Shares Held
8.6M
Call Options Held
1M
Put Options Held
100
View Full List

About EAGLE PHARMACEUTICALS, INC.

EGRX Quotes by TradingView
  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $7.55M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email